A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II
Open Access
- 22 December 2021
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (7) , 856-866
Abstract
Summary: Background: The optimal choice of biological agents after failure of anti‐tumour‐necrosis‐factor‐(TNF)α agent in Crohn’s disease (CD) is yet to be defined.Aims: To assess the effectiveness and safety of ustekinumab compared to vedolizumab as second‐line treatment in CD patients who failed anti‐TNFα therapy.Methods: Retrospective analysis of clinical response and remission at 14 and 52 weeks to ustekinumab by physician global assessment (PGA). A propensity score‐matched analysis with a cohort treated with vedolizumab was performed.Results: Of 282 patients (mean age 40 ± 15, F:M ratio 1.7:1) treated with ustekinumab, clinical response or remission was reached by 200/282 patients (70.9%) at 14 weeks, and 162/259 patients (62.5%) at 52 weeks. Overall, 74 adverse events occurred, of which 26 were labelled as serious (8.3 per 100 person‐year). After exclusion of patients without prior anti‐TNFα exposure and patients previously exposed to vedolizumab or ustekinumab, we analysed 275/282 patients (97.5%) on ustekinumab and 118/135 patients (87.4%) on vedolizumab. Propensity score analysis revealed that at 14 weeks, patients treated with ustekinumab were 38% (95% CI 25%‐50%; P < 0.001) more likely to achieve clinical remission, while at 52 weeks, the difference of 9% (95% CI −15% to 33%; P = 0.462) was not significant.Conclusions: Ustekinumab was effective and well tolerated in this real‐world cohort. While ustekinumab proved more effective at 14‐weeks, we found no statistically significant differences at 52 weeks compared to vedolizumab.Keywords
Funding Information
- Janssen Pharmaceutica
This publication has 41 references indexed in Scilit:
- Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment RegistryJournal of the American Academy of Dermatology, 2017
- Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?World Journal of Gastroenterology, 2017
- Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohnʼs DiseaseInflammatory Bowel Diseases, 2017
- Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohortAlimentary Pharmacology & Therapeutics, 2017
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseNew England Journal of Medicine, 2016
- Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)Annals of the Rheumatic Diseases, 2016
- On regression adjustment for the propensity scoreStatistics in Medicine, 2014
- Malignant melanoma during ustekinumab therapy of Crohnʼs diseaseInflammatory Bowel Diseases, 2012
- Discovery and mechanism of ustekinumabmAbs, 2011
- The impact of biologics on health-related quality of life in patients with inflammatory bowel diseaseClinical and Experimental Gastroenterology, 2009